Thank you
This live web event has ended. Thank you for attending.
Description
Dr. Jason
Goldman is an infectious disease physician, epidemiologist, and clinical
researcher who has been an investigator in multiple clinical trials evaluating
different therapies in the treatment of COVID-19 during the pandemic. He will
provide an overview of the current treatment landscape for patients who have
been hospitalized with COVID-19 as recommended by the NIH COVID-19 Treatment
Guidelines, including remdesivir, dexamethasone, baricitinib, and tocilizumab.
Key data from pivotal clinical trials of these drugs, including time to
recovery, mortality, and safety, will be discussed, providing the evidence base
for their use in hospitalized COVID-19 patients.
This program is sponsored by Eli Lilly and Company.
By registering for this
webinar, you agree your information will be shared with the sponsor.
No CME or MOC credits are
available for this program.
Opinions expressed and
resources shared may not have been reviewed by the ATS prior to distribution
through ATS channels, or reflect official positions of the ATS, unless it is
explicitly noted as a result of official ATS approval. References to specific commercial
entities (companies) or products do not reflect review or endorsement by the
ATS unless it is explicitly noted as a result of official ATS approval.